Organization | Cancer League of Colorado, Inc

Cancer League of Colorado, Inc Report issue

Foundation Phase 1 Phase 2

Organization Overview

First Clinical Trial

2019

NCT03734653

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Cancer League of Colorado | Cancer League of Colorado, Inc

Active Ingredients

Drugs in Phase 2 Trials (4)

axitinib (inlyta) (1 trial)

nivolumab (opdivo) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (2 trials)

Drugs in Phase 1 Trials (5)

enzalutamide (xtandi) (1 trial)

lorlatinib (lorbrena) (1 trial)

osimertinib (tagrisso) (1 trial)

temozolomide (temodar) (1 trial)

testosterone (delatestryl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Colorectal Neoplasms (Phase 2)

Microsatellite Instability (Phase 2)

Prostatic Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 9